Armstrong Shaw Associates Incct Lowers stake in Amgen (AMGN)

Amgen (AMGN) : Armstrong Shaw Associates Incct reduced its stake in Amgen by 0.11% during the most recent quarter end. The investment management company now holds a total of 68,549 shares of Amgen which is valued at $11,819,904 after selling 73 shares in Amgen , the firm said in a disclosure report filed with the SEC on Aug 8, 2016.Amgen makes up approximately 2.89% of Armstrong Shaw Associates Incct’s portfolio.

Other Hedge Funds, Including , Mesirow Financial Investment Management – Equity Management reduced its stake in AMGN by selling 2,760 shares or 49.45% in the most recent quarter. The Hedge Fund company now holds 2,821 shares of AMGN which is valued at $486,425. Amgen makes up approx 0.03% of Mesirow Financial Investment Management – Equity Management’s portfolio.Hudock Capital Group boosted its stake in AMGN in the latest quarter, The investment management firm added 31 additional shares and now holds a total of 1,887 shares of Amgen which is valued at $327,262. Amgen makes up approx 0.18% of Hudock Capital Group’s portfolio.American Century Companies Inc boosted its stake in AMGN in the latest quarter, The investment management firm added 233,315 additional shares and now holds a total of 2,354,433 shares of Amgen which is valued at $401,854,624. Amgen makes up approx 0.44% of American Century Companies Inc’s portfolio.Daiwa Securities Group boosted its stake in AMGN in the latest quarter, The investment management firm added 2,100 additional shares and now holds a total of 20,500 shares of Amgen which is valued at $3,498,940. Amgen makes up approx 0.02% of Daiwa Securities Group’s portfolio.Benjamin F. Edwards Company boosted its stake in AMGN in the latest quarter, The investment management firm added 1,400 additional shares and now holds a total of 7,720 shares of Amgen which is valued at $1,239,214. Amgen makes up approx 0.24% of Benjamin F. Edwards Company’s portfolio.

Amgen opened for trading at $171.48 and hit $174.72 on the upside on Monday, eventually ending the session at $174.58, with a gain of 0.90% or 1.56 points. The heightened volatility saw the trading volume jump to 27,84,334 shares. Company has a market cap of $130,649 M.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.